# Lorenzo Sabatelli

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lorenzo-sabatelli/

## Facts

| Field | Value |
| --- | --- |
| Citations | 809 |
| Field | Dermatology and Skin Diseases |
| h-index | 12 |
| i10-index | 12 |
| Last Known Institution | Galderma (Switzerland) |
| OpenAlex ID | https://openalex.org/A5070517090 |
| ORCID iD | 0000-0001-7373-9306 |
| Works | 50 |

## Researcher papers

- [Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics](https://scholariq.org/papers/epidemiological-benefits-of-more-effective-tuberculosis-vaccines-drugs-and/)
- [Waiting time distributions in financial markets](https://scholariq.org/papers/waiting-time-distributions-in-financial-markets/)
- [Non-monotonic spontaneous magnetization in a Sznajd-like consensus model](https://scholariq.org/papers/non-monotonic-spontaneous-magnetization-in-a-sznajd-like-consensus-model/)
- [A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America](https://scholariq.org/papers/a-cost-effectiveness-analysis-of-denosumab-for-the-prevention-of-skeletal/)
- [PHASE TRANSITIONS, MEMORY AND FRUSTRATION IN A SZNAJD-LIKE MODEL WITH SYNCHRONOUS UPDATING](https://scholariq.org/papers/phase-transitions-memory-and-frustration-in-a-sznajd-like-model-with-synchronous/)
- [Cost-effectiveness and Budget Impact of Routine Use of Fractional Exhaled Nitric Oxide Monitoring for the Management of Adult Asthma Patients in Spain](https://scholariq.org/papers/cost-effectiveness-and-budget-impact-of-routine-use-of-fractional-exhaled-nitric/)
- [RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma](https://scholariq.org/papers/re-mind2-comparative-effectiveness-of-tafasitamab-plus-lenalidomide-versus/)
- [Langevin processes, agent models and socio-economic systems](https://scholariq.org/papers/langevin-processes-agent-models-and-socio-economic-systems/)
- [Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison](https://scholariq.org/papers/ponatinib-vs-imatinib-as-frontline-treatment-for-philadelphia-chromosome/)
- [Modelling heterogeneity and the impact of chemotherapy and vaccination against human hookworm](https://scholariq.org/papers/modelling-heterogeneity-and-the-impact-of-chemotherapy-and-vaccination-against/)
- [Healthcare Resource Utilization and Economic Burden Across Clinical Phenotypes of Moderate-to-Severe Atopic Dermatitis in United States Dermatology Facilities](https://scholariq.org/papers/healthcare-resource-utilization-and-economic-burden-across-clinical-phenotypes/)

## Researcher topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Complex Systems and Time Series Analysis](https://scholariq.org/topics/complex-systems-and-time-series-analysis/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)

## Researcher university

- [Galderma (Switzerland)](https://scholariq.org/institutions/galderma-switzerland/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.